OTCMKTS:HKMPY Hikma Pharmaceuticals (HKMPY) Stock Price, News & Analysis → AI Bubble Now at Critical Mass (From Porter & Company) (Ad) Free HKMPY Stock Alerts $47.48 -1.22 (-2.51%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$47.48▼$47.4850-Day Range$47.58▼$51.6552-Week Range$41.50▼$56.63Volume225 shsAverage Volume436 shsMarket CapitalizationN/AP/E Ratio15.34Dividend Yield0.67%Price TargetN/A Stock AnalysisStock AnalysisChartDividendHeadlinesShort InterestStock AnalysisChartDividendHeadlinesShort Interest Get Hikma Pharmaceuticals alerts: Email Address Ad Porter & CompanyAI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.Simply click here now to read The Big AI Die-Up. About Hikma Pharmaceuticals Stock (OTCMKTS:HKMPY)Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms in North America, the Middle East, North Africa, and Europe. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company was founded in 1978 and is headquartered in London, the United Kingdom.Read More HKMPY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HKMPY Stock News HeadlinesFebruary 22, 2024 | msn.comHikma shares spike after pharma giant’s profit up 30 per centFebruary 21, 2024 | prnewswire.comHikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facilityMarch 28, 2024 | Porter & Company (Ad)AI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.February 5, 2024 | finanznachrichten.deHikma Pharmaceuticals USA Inc.: Hikma announces US launch of COMBOGESIC IVFebruary 5, 2024 | markets.businessinsider.comHikma Pharma Launches Pain Relief Injection COMBOGESIC IV In USFebruary 5, 2024 | finance.yahoo.comHikma announces US launch of COMBOGESIC® IVJanuary 22, 2024 | finance.yahoo.comActiv Surgical Announces Completion of First International Procedure Using Its ActivSight™ Intelligent LightJanuary 8, 2024 | finance.yahoo.comGuardant Health and Hikma Partner to Offer Cancer Screening and Comprehensive Genomic Profiling Tests in the Middle East and North AfricaMarch 28, 2024 | Porter & Company (Ad)AI Bubble Now at Critical MassWashington, D.C., has just issued its first round of new artificial-intelligence (“AI”) regulations. And a flood of additional AI bills is making its way through Congress. Nasdaq reports this could bring a screeching halt to the AI stock boom.November 6, 2023 | finance.yahoo.comHikma Pharmaceuticals PLC's (LON:HIK) institutional investors lost 5.8% over the past week but have profited from longer-term gainsAugust 17, 2023 | msn.comSK Biopharm inks license deal with Hikma's Middle East unitAugust 15, 2023 | marketwatch.comHikma Pharmaceuticals outperforms market despite losses on the dayAugust 8, 2023 | msn.comHikma Pharmaceuticals goes ex dividend tomorrowAugust 6, 2023 | finance.yahoo.comIs It Worth Considering Hikma Pharmaceuticals PLC (LON:HIK) For Its Upcoming Dividend?June 27, 2023 | thestreet.comHikma Trims Full-Year Revenue Guidance After Advair Diskus DelayJune 15, 2023 | finance.yahoo.comHikma exceeds 150 injectable medicines in the US with launch of Dobutamine Injection, USPMay 31, 2023 | uk.finance.yahoo.comFTSE 100: Ocado at risk, IMI in – how London Stock Exchange is set to reshuffle the indexMay 5, 2023 | marketwatch.comHikma Pharmaceuticals rises Friday, still underperforms marketMay 3, 2023 | marketwatch.comHikma Pharmaceuticals rises Wednesday, outperforms marketMarch 19, 2023 | finance.yahoo.comHikma Pharmaceuticals Full Year 2022 Earnings: EPS Misses ExpectationsFebruary 7, 2023 | uk.investing.comHikma Pharmaceuticals PLC (HIK)January 31, 2023 | marketwatch.comHikma Pharmaceuticals rises Tuesday, outperforms marketJanuary 24, 2023 | marketwatch.comHikma Pharmaceuticals falls Tuesday, underperforms marketDecember 27, 2022 | msn.comJunshi inks licensing deal with Hikma for toripalimab; FDA filing still under reviewDecember 26, 2022 | financialpost.comJunshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa RegionDecember 15, 2022 | marketwatch.comHikma Pharmaceuticals rises Thursday, outperforms marketOctober 9, 2022 | finance.yahoo.comHikma Pharmaceuticals PLC (HKMPY)See More Headlines Receive HKMPY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Ex-Dividend for 5/13 Dividend3/21/2024Today3/28/2024Dividend Payable5/13/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:HKMPY CUSIPN/A CIKN/A Webwww.hikma.com Phone442073992760FaxN/AEmployees9,100Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio15.34 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesEngineer Said Samih Taleb Darwazah (Age 67)Executive Chairman Comp: $2.97MMr. Mazen Samih Taleb Darwazah (Age 66)Executive Vice Chairman & President of MENA Comp: $1.95MMr. Riad MishlawiCEO & DirectorMr. Khalid Waleed Hosny Al Nabilsi (Age 52)Chief Financial Officer Mr. Guy FeatherstoneAssociate Director of Investor RelationsMr. Bassam Wael Rushdi Kanaan CFA (Age 59)CPA, Executive VP of Corporate Development and M&A Mr. Hussein Omar ArkhaghaChief People OfficerMs. Susan RingdalExecutive VP of Strategic Planning & Global AffairsMr. Brian HoffmannPresident of GenericsMr. Samuel ParkGlobal Head of Intellectual Property (IP) & General Counsel for USMore ExecutivesKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors HKMPY Stock Analysis - Frequently Asked Questions How have HKMPY shares performed in 2024? Hikma Pharmaceuticals' stock was trading at $45.4110 at the beginning of the year. Since then, HKMPY shares have increased by 4.6% and is now trading at $47.4795. View the best growth stocks for 2024 here. Are investors shorting Hikma Pharmaceuticals? Hikma Pharmaceuticals saw a decrease in short interest during the month of February. As of February 29th, there was short interest totaling 100 shares, a decrease of 50.0% from the February 14th total of 200 shares. Based on an average trading volume of 600 shares, the days-to-cover ratio is presently 0.2 days. View Hikma Pharmaceuticals' Short Interest. How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals declared a dividend on Wednesday, March 6th. Shareholders of record on Friday, March 22nd will be paid a dividend of $0.92 per share on Monday, May 13th. The ex-dividend date of this dividend is Thursday, March 21st. This is a boost from the stock's previous dividend of $0.48. Read our dividend analysis for HKMPY. Is Hikma Pharmaceuticals a good dividend stock? Hikma Pharmaceuticals (OTCMKTS:HKMPY) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.65%. The dividend payout ratio is 10.34%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for HKMPY. How do I buy shares of Hikma Pharmaceuticals? Shares of HKMPY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HKMPY) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hikma Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.